Developing biomarkers to predict benefit from HGF/MET pathway inhibitors

Publisher： John Wiley & Sons Inc

E-ISSN： 1555-2039|232|2|210-218

ISSN： 0022-3417

Source： THE JOURNAL OF PATHOLOGY, Vol.232, Iss.2, 2014-01, pp. : 210-218

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 2, 2011-05 ,pp. : 228-233

Bentham Science Publishers

Access to resources Recommend Favorite

Ezrin mediates both HGF/Met autocrine and non‐autocrine signaling‐induced metastasis in melanoma

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 8, 2018-04 ,pp. : 1652-1663

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ovarian cancer ascites enhance the migration of patient‐derived peritoneal mesothelial cells viacMet pathway through HGF‐dependent and ‐independent mechanisms

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 2, 2015-07 ,pp. : 289-298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Induction of insulin‐producing cells from umbilical cord blood‐derived stromal cells by activation of the c‐Met/HGF axis

By  

DEVELOPMENT, GROWTH & DIFFERENTIATION (ELECTRONIC), Vol. 57, Iss. 5, 2015-06 ,pp. : 353-361

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma

By  

BJU INTERNATIONAL, Vol. 115, Iss. 6, 2015-06 ,pp. : 854-855

John Wiley & Sons Inc

Access to resources Recommend Favorite